For at least five decades this unique non-suppurative sequel to group A streptococcal infections has been a concern of the World Health Organization and its member countries. Sentinel studies conducted under the auspices of the WHO during the last four decades clearly documented that the control of the preceding infections and their sequelae is both cost effective and inexpensive. Without doubt, appropriate public health control programs and optimal medical care reduce the burden of disease (1–6)
